• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Target ALS

A New York based ALS research organization that's leading the fight for a cure.

  • DONATE
  • About Us
    • Our Mission
    • Our Model
    • Our Impact
    • Our Founder
    • Our Team
    • Our Partners
  • For Scientists
    • Research Cores
      • Target ALS Data Engine
      • Longitudinal Biofluids Core
      • Human Postmortem Tissue Core
      • Stem Cell Core
      • Reagents Core
      • Animal Models Core
    • Funding Opportunities
    • Funded Projects
    • Annual Meeting
    • Science on Target Blog
  • Understanding ALS
    • The Science, Explained
      • Glossary
      • FAQ
      • ALS 101
    • Voices of ALS
    • Video Library
  • Take Action
    • ALS Awareness Month:
      Behind the Breakthrough
    • Support Geoff Greulich
    • The ALS Global Research Initiative (AGRI)
      • Global Natural History Study
      • Community Based Pop-Up Clinics
    • Ways to Give
    • Email Sign Up
    • Contact Us
    • Donate Now
  • News
    • Announcements
    • In the News
    • Newsletters & Reports

Research

ALS and Other Motor Neuron Diseases: What’s the Difference?

steckinsights · Jan 4, 2022 ·

neurons

The Stages of ALS: Framing the Progression of a Nonlinear Disease

steckinsights · Jan 4, 2022 ·

neurons

Under the Microscope: Gene Yeo on RNA-Directed Therapy for ALS Caused by a C9ORF72 Mutation

steckinsights · Oct 11, 2021 ·

Under the Microscope: Christine Vande Velde on Seeking Solutions for Cellular Self Defense

steckinsights · Jul 8, 2021 ·

neurons

UNDER THE MICROSCOPE: Why TDP-43 Matters So Much in ALS Research

steckinsights · Jul 7, 2020 ·

UNDER THE MICROSCOPE: Ludo Van Den Bosch on Returning to Work, Exploring Therapeutic Strategies to Battle ALS & FTD

steckinsights · Jun 2, 2020 ·

Ludo Van Den Bosch

Target ALS Expands Stem Cell Core to Include Innovative New Reporter Lines

steckinsights · Jan 31, 2020 ·

Thanks to Your Support: $35 Million Raised in 2019

steckinsights · Jan 2, 2020 ·

Raising $35 million in 2019

A Cancer Drug for ALS? Organization Forges Promising ALS Treatment, an Innovative Approach to Incubate Novel Therapeutics

steckinsights · Dec 19, 2019 ·

  • Page 1
  • Page 2
  • Go to Next Page »

Footer

Target ALS
  • Donate
  • Contact
  • Financial Reports
  • Call For Proposals
  • Annual Meeting
  • Privacy Policy
  • Credits

Follow Us

guidestar

We are a 501(c)(3) public charity (EIN: 81-0756743), eligible to receive tax-deductible contributions that directly support our mission to break down barriers to ALS research to find effective treatments.

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

© 2023 Target ALS Foundation, Inc.
Target ALS Foundation
244 Madison Avenue #1025
New York, NY 10016
(332) 333-4140
Steck Insights WordPress Consulting